Related Experiment Video
Updated: Feb 17, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
Published on: September 17, 2015
The Diuretic Potential of Sacubitril/Valsartan: A Tale of 2 Patients
Sabrina M Hormann1, Lindsay E Davis, Elizabeth K Pogge
1Sabrina M. Hormann, PharmD Compounding Pharmacist, Potter's House Apothecary, Peoria, Arizona. Lindsay E. Davis, PharmD, BCPS, ASH-CHC, TTS Associate Professor, College of Pharmacy-Glendale, Midwestern University, Arizona. Elizabeth K. Pogge, PharmD, MPH, BCPS-AQ (Cardiology), FASCP Associate Professor, College of Pharmacy-Glendale, Midwestern University, Arizona.
Insights
Angiotensin receptor-neprilysin inhibitor (ARNi) therapy in heart failure patients led to improved fluid balance and reduced diuretic needs. This suggests ARNi promotes beneficial diuresis, potentially optimizing treatment regimens.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Rising heart failure prevalence in the US incurs significant morbidity, mortality, and healthcare costs.
- 2016 guidelines recommend angiotensin receptor-neprilysin inhibitors (ARNi) for stage C heart failure with reduced ejection fraction (HFrEF).
- ARNi therapy is advised for chronic HFrEF patients (NYHA class II-III) to further reduce morbidity and mortality.
Background:
Heart failure prevalence continues to rise in the United States causing significant morbidity and mortality and costing billions in healthcare expenditures. Consensus guidelines updated in 2016 recommend an angiotensin receptor-neprilysin inhibitor (ARNi) as a therapeutic option in lieu of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for the management of stage C heart failure with reduced ejection fraction (HFrEF). For chronic HFrEF patients with New York Heart Association class II or III symptoms tolerating an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, a change in therapy to an ARNi is recommended to further reduce morbidity and mortality.
Purpose:
We present a brief case series of 2 patients initiated on ARNi therapy for treatment of HFrEF and evaluate their fluid status and diuretic needs before and after ARNi dose optimization.
Conclusions:
After titration to target-dose ARNi therapy, both patients demonstrated improved fluid and electrolyte balance, as well as a reduction in diuretic therapy requirements, suggesting a mechanism of diuresis attributable to ARNi therapy.
Clinical Implications:
Angiotensin receptor-neprilysin inhibitor therapy seems to promote a clinically relevant diuresis in heart failure patients because of increased levels of functioning natriuretic peptides. Awareness of this diuretic potential may allow for optimization of heart failure regimens with pharmacologic agents demonstrated to improve morbidity and mortality, while preventing adverse effects that may occur with overdiuresis.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management
Antihypertensive Drugs: Action of Diuretics
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Thiazide-Class Diuretics
